Voriconazole is a drug that treats infections caused by fungi.
A study conducted at the University of São Paulo (USP) in Brazil shows that brilacidin, a new drug tested for treatment of diseases ranging from bacterial skin infections to COVID-19, can kill drug-resistant strains of fungi when combined with two classes of antifungals available on the market.
CDC reports an outbreak involving Candida auris (C. auris) in Israel.
A recent study published in the journal Biomedicines aimed to determine the antifungal tolerance of Candida auris (C. auris) to all three classes of antifungal drugs commonly used to treat invasive candidiasis.
Researchers from Brazil presented a fatal case of a patient developing Saccharomyces cerevisiae infection and succumbing to septic shock after contracting and recovering from a SARS-CoV-2 infection.
Researchers presented a case series of patients with coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA). The goal of the study was to inform clinicians and healthcare workers of this serious COVID-19-related complication.
In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.
Researchers analyze literature to explore the frequency of secondary fungal infections among COVID-19 patients.
A new study led by Imperial College London finds that drug-resistant mold is spreading from the environment and infecting susceptible people's lungs.
A new study published in the British Journal of Clinical Pharmacology provides insights on how common hospitalized patients develop liver injury from taking different medications.
Scientists have developed a pioneering new procedure that will help diagnose a potentially lethal fungal lung disease with greater speed and accuracy, and with less distress to the patient.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.
New therapies are improving care, but early diagnosis remains critical in the effective treatment of invasive, a potentially deadly fungal infection, according to new guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases.
Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers.
Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis.
Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa.
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.
Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.